Daniel Catenacci Profile picture
Medical Oncologist. "Targeted therapies for targeted populations”

Sep 27, 2019, 9 tweets

FIGHT-202 anti-FGFR2 pemigatinib for FGFR2 fusion cholangiocarcinoma. Very impressive

3-arm non-randomized phase 2

Primary endpoint ORR in cohort A FGFR2 fusion cohort

Incidence of FGFR2 fusion:

35% ORR

PFS

OS

Enough for accelerated conditional approval???

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling